Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.00001 par value
Symbol
ACRS on Nasdaq
Shares outstanding
119,747,899
Price per share
$2.64
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
61,101,786
Total reported value
$183,913,298
% of total 13F portfolios
0%
Share change
-1,139,008
Value change
-$3,159,855
Number of holders
79
Price from insider filings
$2.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 12% -11% $37,620,000 14,250,000 0% BML Investment Partners, L.P. 31 Dec 2025
Bonita Biotech (HK) Ltd 9.4% $33,944,003 11,281,950 Biosion, Inc. 09 Dec 2025
BlackRock, Inc. 6.2% +22% $20,164,873 +$3,698,306 6,700,629 +22% BlackRock, Inc. 31 Dec 2025
VANGUARD GROUP INC 6.2% +31% $9,460,129 +$2,402,369 6,662,063 +34% The Vanguard Group 30 Jun 2025
Adage Capital Management, L.P. 4.9% -34% $10,028,474 -$5,554,080 5,278,144 -36% Adage Capital Management, L.P. 30 Sep 2025
Rock Springs Capital Management LP 4.7% $7,720,853 5,046,309 Rock Springs Capital Management LP 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.5% -32% $5,449,080 -$2,422,176 3,837,380 -31% Millennium Management LLC 30 Jun 2025

As of 31 Dec 2025, 79 institutional investors reported holding 61,101,786 shares of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS). This represents 51% of the company’s total 119,747,899 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 12% 14,250,000 0% 38% $42,892,500
Vivo Capital, LLC 7.4% 8,888,888 0% 1.7% $26,755,553
BlackRock, Inc. 5.7% 6,804,841 +20% 0% $20,482,572
VANGUARD GROUP INC 5.4% 6,502,080 -0.21% 0% $19,571,260
Decheng Capital LLC 3.4% 4,041,736 0% 1.6% $12,165,625
MORGAN STANLEY 2.9% 3,415,390 -16% 0% $10,280,323
GEODE CAPITAL MANAGEMENT, LLC 2% 2,392,772 +0.14% 0% $7,204,302
ACADIAN ASSET MANAGEMENT LLC 1.8% 2,122,399 -8.8% 0.01% $6,385,000
STATE STREET CORP 1.3% 1,506,403 +35% 0% $4,534,273
Connor, Clark & Lunn Investment Management Ltd. 1.2% 1,434,164 +34% 0.01% $4,316,834
RENAISSANCE TECHNOLOGIES LLC 0.94% 1,125,331 -31% 0.01% $3,387,246
DEUTSCHE BANK AG\ 0.82% 987,351 +6.9% 0% $2,971,927
Aldebaran Capital, LLC 0.8% 954,262 -3.4% 2.6% $2,872,329
Bollard Group LLC 0.67% 804,445 -34% 0.06% $2,421,000
Three Bridge Wealth Advisors, LLC 0.6% 714,823 0% 0.57% $2,151,617
GOLDMAN SACHS GROUP INC 0.53% 632,502 -34% 0% $1,903,831
JPMORGAN CHASE & CO 0.52% 625,963 -17% 0% $1,884,148
MARSHALL WACE, LLP 0.41% 485,501 -72% 0% $1,461,358
Aisling Capital Management LP 0.36% 434,455 0% 0.27% $1,307,710
UBS Group AG 0.3% 362,538 +245% 0% $1,091,240
HighTower Advisors, LLC 0.26% 305,948 -1.1% 0% $920,903
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.24% 284,604 +18% 0% $856,658
DIMENSIONAL FUND ADVISORS LP 0.23% 270,850 +65% 0% $814,644
Nuveen, LLC 0.2% 237,830 0% 0% $715,868
Bank of New York Mellon Corp 0.17% 203,517 -7.5% 0% $612,586

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 61,101,786 $183,913,298 -$3,159,855 $3.01 79
2025 Q3 85,675,311 $162,782,120 -$11,317,612 $1.90 103
2025 Q2 91,862,480 $130,443,350 -$2,093,251 $1.42 95
2025 Q1 92,164,636 $141,009,418 +$2,108,864 $1.53 106
2024 Q4 87,478,919 $216,988,373 +$93,728,957 $2.48 97
2024 Q3 50,891,008 $58,523,068 -$1,742,222 $1.15 76
2024 Q2 52,848,132 $58,129,308 -$1,619,597 $1.10 93
2024 Q1 54,386,842 $67,436,941 -$3,788,067 $1.24 93
2023 Q4 58,449,543 $61,369,526 -$207,123,774 $1.05 102
2023 Q3 70,071,814 $479,974,125 -$28,113,579 $6.85 137
2023 Q2 71,014,841 $736,442,996 +$5,835,766 $10.37 131
2023 Q1 71,610,627 $579,302,266 +$19,605,105 $8.09 148
2022 Q4 65,900,596 $1,037,946,141 -$2,542,115 $15.75 126
2022 Q3 63,675,444 $1,002,225,041 +$5,530,098 $15.74 124
2022 Q2 63,269,555 $883,318,693 +$55,162,166 $13.96 112
2022 Q1 59,295,213 $1,021,908,185 +$59,352,437 $17.24 107
2021 Q4 56,045,310 $814,890,981 -$39,784,690 $14.54 133
2021 Q3 56,785,960 $1,022,155,424 +$15,328,009 $18.00 126
2021 Q2 56,004,936 $983,410,407 +$20,628,850 $17.56 128
2021 Q1 45,417,666 $1,298,594,000 +$509,363,836 $25.20 95
2020 Q4 31,934,018 $206,591,000 +$27,717,112 $6.47 79
2020 Q3 25,553,008 $65,673,000 -$3,889,513 $2.57 52
2020 Q2 28,456,883 $46,099,261 -$5,512,533 $1.62 56
2020 Q1 32,079,500 $33,361,056 +$3,161,589 $1.04 65
2019 Q4 30,811,789 $58,227,600 +$3,325,295 $1.89 72
2019 Q3 29,070,550 $31,395,961 -$19,214,772 $1.08 76
2019 Q2 35,610,940 $77,957,966 -$16,270,841 $2.19 82
2019 Q1 37,867,320 $227,075,061 -$11,074,522 $5.99 91
2018 Q4 39,079,487 $288,764,092 +$36,606,178 $7.39 95
2018 Q3 29,659,351 $430,705,323 -$29,549,131 $14.52 81
2018 Q2 30,998,695 $618,964,700 +$11,707,281 $19.97 92
2018 Q1 30,570,960 $535,621,157 +$33,812,143 $17.52 100
2017 Q4 28,517,743 $703,264,074 -$10,560,834 $24.66 102
2017 Q3 28,502,689 $696,914,157 +$73,632,695 $25.81 102
2017 Q2 25,609,895 $694,432,125 +$43,716,393 $27.12 101
2017 Q1 23,711,078 $707,195,746 +$74,703,828 $29.82 111
2016 Q4 21,351,804 $579,490,455 +$95,769,317 $27.14 100
2016 Q3 15,510,238 $397,182,894 +$4,351,904 $25.61 59
2016 Q2 15,355,135 $283,613,231 +$13,304,019 $18.47 47
2016 Q1 14,605,233 $276,749,000 +$2,035,314 $18.95 34
2015 Q4 10,288,500 $277,169,982 +$277,169,982 $26.94 33